title: Human immunodeficiency virus infection of human lymph nodes in the SCID-hu mouse.
abstract: The SCID-hu mouse is a small animal in which human hematolymphoid organs can be engrafted and maintained in vivo. In this study, parameters are described for reproducible infection of SCID-hu mice after i.v. inoculation. Infection was found to be dependent upon the time after inoculation, the virus isolate, the titer of virus, and the human target organ implanted into the mouse. Ten to 14 days after the i.v. administration of HIV isolates derived freshly from patients (e.g., JR-CSF, JR-FL, SM), 100% of engrafted human lymph nodes in SCID-hu mice were infected; greater than 95% of these animals were also viremic. Implants of human thymus or connective tissue, as well as the endogenous murine hematolymphoid organs, were not infected. As demonstrated by a combination of in situ hybridization and immunohistochemistry, both T-lymphoid and myelomonocytic lineage cells were infected in this system. HIV isolates that have been adapted to growth in vitro (e.g., HTLV-IIIb) were not infectious. When either 3'-azido-3'-deoxythymidine (AZT) or 2',3'-dideoxyinosine (ddIno) was administered to SCID-hu mice before HIV infection, the animals were protected in dose ranges similar to those used in man. This animal model may now be used as an efficient intermediate step between the lab and the clinic to study the infectious process in vivo and to best select efficacious antiviral compounds against HIV.
authors.affiliation: HIV Group, SyStemix, Inc., Palo Alto, CA 94303.
authors.forename: H
authors.initials: H
authors.lastname: Kaneshima
authors.forename: C C
authors.initials: CC
authors.lastname: Shih
authors.forename: R
authors.initials: R
authors.lastname: Namikawa
authors.forename: L
authors.initials: L
authors.lastname: Rabin
authors.forename: H
authors.initials: H
authors.lastname: Outzen
authors.forename: S G
authors.initials: SG
authors.lastname: Machado
authors.forename: J M
authors.initials: JM
authors.lastname: McCune
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D004279:DNA, Viral / Q000032:analysis; D016049:Didanosine / Q000627:therapeutic use; D006678:HIV / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D015658:HIV Infections / Q000382:microbiology* / Q000517:prevention & control; D006801:Humans; D007150:Immunohistochemistry; D007153:Immunologic Deficiency Syndromes / Q000382:microbiology*; D008198:Lymph Nodes / Q000382:microbiology / Q000637:transplantation*; D008264:Macrophages / Q000382:microbiology; D051379:Mice; D009693:Nucleic Acid Hybridization; D016133:Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000382:microbiology; D014183:Transplantation, Heterologous; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D015215:Zidovudine; D016049:Didanosine